Increased TILs were shown to positively correlate with neoadjuvant treatment response and clinical benefit in early HER2+ BC, similar to what was seen in TNBC, according to several studies evaluating the role of TILs in this cancer [8,59,67]. Here, ERBB2 is linked to breast cancer.